Kezar Life Sciences

Today, we announced our participation at two upcoming investor conferences! Learn more about our upcoming presentations in our latest press release here: ir.kezarlifesciences.com/news-releases/…

Today, we released our second quarter 2025 financial results along with recent business updates. Learn more in the full news release here: ir.kezarlifesciences.com/news-releases/…

Today, we celebrate 10 years of incredible science, dedication, and teamwork! We couldn't have reached this milestone without our amazing employees, the physicians at our clinical trial sites, and the patients and their caregivers. Thank you for your passion and purpose!

Tomorrow, Kezar’s CEO, Chris Kirk, will participate in a fireside chat at the Jefferies Global Healthcare Conference! A webcast of the discussion will be available on our website's “Events & Presentations” section here: ir.kezarlifesciences.com/events/event-d… #JefferiesHealthcare

Today, we announced our participation in the Jefferies Global Healthcare Conference in #NewYorkCity next week. Learn more about our upcoming fireside chat in our latest press release here: ir.kezarlifesciences.com/news-releases/… #JefferiesHealthcare

Today, we released our first quarter 2025 financial results along with recent business updates. Learn more in the full news release here: ir.kezarlifesciences.com/news-releases/…

Celebrating the incredible moms who fill our world with love, laughter, and strength — for families of all kinds. Happy Mother’s Day!

Today, we released our second quarter 2024 financial results along with recent business updates. Learn more in the full news release here: ir.kezarlifesciences.com/news-releases/…

We are excited to share that our partner, Everest Medicines, has dosed the first patient in China. Their team continues to integrate seamlessly with ours to drive forward our global Phase 2b clinical trial evaluating zetomipzomib in adults living with LN. everestmedicines.com/news/everest-m…

Zetomipzomib is the only selective immunoproteasome inhibitor being evaluated in clinical trials for lupus nephritis. Learn more about the PALIZADE trial at PALIZADEtrial.com. #PALIZADEtrial #zetomipzomib #LupusNephritis

Kezar hit a home run with a company outing to Oracle Park. Nothing beats a day at the park with a team that feels like family.

Here’s to the fathers who inspire us every day. Happy Father’s Day.

Tomorrow, Kezar’s CEO Chris Kirk will participate in a fireside chat at the Jefferies Global Healthcare Conference! A webcast of the discussion will be available on our website's “Events & Presentations” section here: ir.kezarlifesciences.com/news-events/ev…. #Jefferies #Healthcare #LN

Lupus nephritis is a frequent and moderate-to-severe complication of lupus affecting the kidneys. Learn about Kezar’s selective immunoproteasome inhibitor zetomipzomib being evaluated for those living with lupus nephritis: PALIZADEtrial.com. #LupusAwarenessMonth

Today, we announced our participation in the Jefferies Global Healthcare Conference in #NewYorkCity next week. Learn more about our upcoming fireside chat in our latest press release here: ir.kezarlifesciences.com/news-releases/… #Jefferies #Healthcare #Zetomipzomib

Learn more about the PALIZADE trial by visiting lnkd.in/gtxDfybE. #PALIZADEtrial #zetomipzomib

From our families to yours, Happy Mother's Day. #mothersday

May 10th is World Lupus Day. Let’s #PutOnPurple to help #MakeLupusVisible. #WorldLupusDay #POP #LAM

Today, we announced our first quarter 2024 financial results, including recent business updates. Learn more in the full news release here: ir.kezarlifesciences.com/news-releases/…

May is Lupus Awareness Month. Lupus is an autoimmune disease that causes chronic inflammation and organ damage. Lupus can affect anyone at any age and isn’t necessarily visible. Kezar invites you to promote lupus visibility by wearing purple this month! #LAM #PutOnPurple